Stocktoria
Fulgent Genetics, Inc. FLGT
Fulgent Genetics, Inc. (FLGT) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $322.7M at a -18.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.32 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.384 |
| Retained earnings / assets | 0.437 |
| EBIT / assets | -0.075 |
| Equity / liabilities | 10.411 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| FLGT | Fulgent Genetics, Inc. | 3/9 | 14.37 | — | +13.8% |
| BLLN | BillionToOne, Inc. | 7/9 | 7.37 | 729.2 | +100% |
| CSTL | CASTLE BIOSCIENCES INC | 3/9 | 6.15 | — | +3.7% |
| CDNA | CareDx, Inc. | 4/9 | 0.16 | — | +13.8% |
| GRAL | GRAIL, Inc. | 4/9 | -2.86 | — | +17.2% |
| VCYT | VERACYTE, INC. | 7/9 | 15.66 | 61.2 | +16% |
| BDSX | BIODESIX INC | 3/9 | -19.59 | — | +24.1% |
About Fulgent Genetics, Inc.
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, large corporations, and patients. Fulgent Genetics, Inc. was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.
FAQ
Is FLGT financially healthy?
Fulgent Genetics, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does FLGT pay a dividend?
No, Fulgent Genetics, Inc. does not currently pay a dividend.
How profitable is FLGT?
In FY2025, Fulgent Genetics, Inc. had a net margin of -18.8% and a return on equity of -5.4%.
What is the analyst price target for FLGT?
The average Wall-Street price target for Fulgent Genetics, Inc. is $18.50, about 1.1% below the recent price, from 2 analysts.
Is FLGT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Fulgent Genetics, Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.